For instance, patients should be considered at high risk if they meet at least two of the following criteria: DM phenotype, positivity for anti-TIF1-γ or anti-NXP2, age >40 years at the onset of IIM, persistent high disease activity despite therapy, dysphagia, and cutaneous necrosis. This evidence concerns the gene MORC3 and dermatomyositis.